Supprelin La is a drug owned by Endo Operations Ltd. It is protected by 1 US drug patent filed in 2013 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Jun 16, 2026. Details of Supprelin La's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US8062652 | Compositions and methods for treating precocious puberty |
Jun, 2026
(1 year, 6 months from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Supprelin La's patents.
Latest Legal Activities on Supprelin La's Patents
Given below is the list of recent legal activities going on the following patents of Supprelin La.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 12 Apr, 2023 | US8062652 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 11 Apr, 2019 | US8062652 |
| Correspondence Address Change Critical | 09 Aug, 2012 | US8062652 |
| Change in Power of Attorney (May Include Associate POA) Critical | 09 Aug, 2012 | US8062652 |
| Post Issue Communication - Certificate of Correction | 24 Apr, 2012 | US8062652 |
| Patent Issue Date Used in PTA Calculation Critical | 22 Nov, 2011 | US8062652 |
| Recordation of Patent Grant Mailed Critical | 22 Nov, 2011 | US8062652 |
| Issue Notification Mailed Critical | 02 Nov, 2011 | US8062652 |
| Dispatch to FDC | 20 Oct, 2011 | US8062652 |
| Miscellaneous Incoming Letter | 11 Oct, 2011 | US8062652 |
FDA has granted several exclusivities to Supprelin La. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Supprelin La, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Supprelin La.
Exclusivity Information
Supprelin La holds 1 exclusivities. All of its exclusivities have expired in 2014. Details of Supprelin La's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE) | May 03, 2014 |
Several oppositions have been filed on Supprelin La's European patents. EP oppositions can significantly impact the timeline for the generic launch of drugs. If an opposition results in the revocation or amendment of a patent, it can shorten the exclusivity period of the original drug. This can lead to an earlier entry of generic versions into the market. To help you estimate the potential early arrival of Supprelin La's generic, the next section provides detailed information on ongoing and past EP oppositions related to Supprelin La patents.
Supprelin La's Oppositions Filed in EPO
Supprelin La has faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Jan 15, 2016, by Actavis Group Ptc Ehf. This opposition was filed on patent number EP05762243A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
 | |||
| EP05762243A | Jan, 2016 | Actavis Group PTC EHF | Revoked |
US patents provide insights into the exclusivity only within the United States, but Supprelin La is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Supprelin La's family patents as well as insights into ongoing legal events on those patents.
Supprelin La's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Supprelin La's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Jun 16, 2026 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Supprelin La Generics:
There are no approved generic versions for Supprelin La as of now.
About Supprelin La
Supprelin La is a drug owned by Endo Operations Ltd. It is used for treating central precocious puberty in children. Supprelin La uses Histrelin Acetate as an active ingredient. Supprelin La was launched by Endo Operations in 2007.
Approval Date:
Supprelin La was approved by FDA for market use on 03 May, 2007.
Active Ingredient:
Supprelin La uses Histrelin Acetate as the active ingredient. Check out other Drugs and Companies using Histrelin Acetate ingredient
Treatment:
Supprelin La is used for treating central precocious puberty in children.
Dosage:
Supprelin La is available in implant form for subcutaneous use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 50MG | IMPLANT | Prescription | SUBCUTANEOUS |